Santhera has begun launch preparations for AGAMREE® in UK with first sales expected in this quarterPratteln, Switzerland, January 16, 2025 – ...

Santhera Pharmaceuticals will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks, after ...

NICE’s positive final guidance for Agamree follows confirmation that no appeals were submitted against its positive December ...

Santhera Pharmaceuticals’ Agamree (vamorolone) has been accepted by the Scottish Medicines Consortium (SMC) to treat Duchenne ...

AGAMREE® is a trademark of Santhera Pharmaceuticals.

The UK’s health technology assessor, the National Institute for Health and Care Excellence (NICE) has issued positive Final Guidance that recommends Agamree (vamorolone) for use in the National Health ...

Santhera gets positive recommendation from Scottish Medicines Consortium for use of Agamree to treat Duchenne muscular dystrophy: Pratteln, Switzerland Wednesday, January 15, 2025 ...

England’s National Institute for Health and Care Excellence (NICE) has recommended Santhera Pharmaceuticals’ treatment for Duchenne muscular dystrophy (DMD) Agamree (vamorolone) following a ...

AGAMREE, a prescription medicine used to treat Duchenne muscular dystrophy (DMD) in patients 2 years of age and older, is approved in several regions, including the U.S., EU, UK, China ...

Santhera's Duchenne muscular dystrophy (DMD) therapy Agamree has been cleared for NHS use after a confidential pricing agreement. The deal means that Agamree (vamorolone) will be available to ...

Pratteln, Switzerland Tuesday, January 7, 2025, 11:00 Hrs [IST] ...

China’s National Medical Products Administration (NMPA) approved AGAMREE® for the treatment of Duchenne muscular dystrophy in patients aged 4 years and older This approval makes AGAMREE the first and ...